April 2025

In an interview with Peers & Perspectives in Oncology, John L. Marshall, MD, discussed treatment approaches and sequencing for refractory colorectal cancer.

During a live event, Shannon N. Westin, MD, MPH, and participants discussed their experience treating patients with progressive cervical cancer and the toxicity profile of tisotumab vedotin.

During a live event, Caron A. Jacobson, MD, MMSc, and participants discussed how they decide on therapy for patients with relapsed/refractory diffuse large B-cell lymphoma.

During a live event, Martin Voss, MD, reviewed the trials of lenvatinib plus pembrolizumab, cabozantinib plus nivolumab, and ipilimumab plus nivolumab in non–clear cell renal cell carcinoma.

During a live event, Marc S. Hoffmann, MD, discussed outcomes from the SEQUOIA and ELEVATE-TN studies in chronic lymphocytic leukemia.

During a a live event, Virginia Kaklamani, MD, DSc, and participants discussed their experiences using a PI3K/AKT inhibitor in patients with metastatic breast cancer.

In a live virtual event, Thomas C. Krivak, MD, reviewed the key studies of PARP inhibitor and bevacizumab maintenance in patients with advanced ovarian cancer.